PAD Profile : Febuxostat - Hyperuricaemia and Gout

PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Febuxostat - Hyperuricaemia and Gout

PAD Profile : Febuxostat - Hyperuricaemia and Gout

Keywords :

Gout, non-purine selective inhibitor, xanthine oxidase

Brand Names Include :

Adenuric

Traffic Light Status

Status 1 of 1.

Status :

Green

Important

Formulations :

Tablets

Important Information :

For patients where allopurinol is not tolerated or contraindicated

Trust Alignment :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

BNF NICE SPC

NFD1

NICE

Comments :

No comments returned.

Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Type

Document

Review Date

NICE Technology Appraisal

NICE TA164 - Febuxostat for the management of hyperuricaemia in people with gout

Policy Statement

Febuxostat for Gout - Policy statement APC 361-2018 Sep18.pdf

Evidence Review

Febuxostat for hyperuricaemia in gout Evidence Review May 2013

Committee Recommendations

Date

Committee Name

Narrative

05 September 2018

Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Prescribing Clinical Network recommends the use of febuxostat in line with NICE TA 164, for the management of chronic hyperuricaemia in gout only for people who are intolerant of allopurinol (as defined in TA) or for whom allopurinol is contraindicated.
Febuxostat is considered to have a GREEN status on the traffic light system

Associated BNF Codes

10. Musculoskeletal and Joint Diseases

10.01.04. Gout and cytotoxic induced hyperuicaemia